Celgene Corporation · Summit, NJ United States (NASDAQ: CELG)
| 86 Morris Ave. | Phone: 908-673-9000 |
| Summit, NJ | Fax: 908-673-9001 |
| 07901 | |
| United States | 
Map This Company |
Celgene Corporation Rankings
| S&P 500 |  #342 in FT Global 500 (June 2011) |
More Companies in These Related Industries: Pharmaceutical Preparation MfgCompany Description
Without cells and genes there would be no us, and without Celgene there would probably be fewer of us. The drug development company's lead product is Revlimid approved in the US and Europe as a treatment for multiple myeloma (bone marrow cancer). Revlimid also is used to treat a malignant blood disease called MDS. The company's second biggest seller is also a treatment for MDS called Vidaza. Other marketed products include Thalomid, used in conjunction with dexamethasone to treat patients newly diagnosed with multiple myeloma, and breast cancer treatment Abraxane. The firm has other drugs in development that combat inflammatory diseases and cancer.
Celgene Corporation Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Public - NASDAQ: CELG Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2010 Employees | 4,182 |
Executives
292 executives listed for Celgene Corporation's Summit, NJ location.
| Chairman, President, and CEO | Robert Hugin | |
|---|---|---|
| Exec Dir | Michele Tenerelli | |
| Executive Director, Medical Aff | Mary Sugrue |